Prostate Cancer

When treatment decisions were made using a prostate genomic classifier after radical prostatectomy in men with prostate cancer, patient outcomes significantly improved.

Single dose radiotherapy may be as effective as 5 doses for patients with spinal canal compression from metastatic cancer.

Researchers indicated that among men age ≥66 with prostate cancer, organ transplant is associated with higher overall mortality but no observable difference in prostate cancer-specific mortality.

The FDA approved enzalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.

Myovant announced that their phase III HERO study of relugolix met its primary efficacy end point and all 6 secondary endpoints in men with advanced prostate cancer.

An international study of prostate cancer clinical trials discovered that opioid use appears to differ by region, implying that a variability should be considered.

Fewer biopsies among men receiving antidiabetic medications may explain the lower prostate cancer risk in men with diabetes.

MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.

Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.

The addition of apalutamide to androgen deprivation therapy is well tolerated and significantly improves survival while maintaining health-related quality of life in men with prostate cancer.

Hyperbaric oxygen therapy can relieve symptoms of late radiation cystitis in patients who underwent radiotherapy of the pelvic region for prostate cancer.

The agency granted breakthrough therapy designation to niraparib for the treatment of men with BRCA1/2-mutant positive metastatic castration-resistant prostate cancer.

Despite prolonged progression-free duration, a 25% reduction in risk of death associated with anti-androgen agent apalutamide fell short of statistical significance in patients with non-metastatic, high-risk castration-resistant prostate cancer.

The findings of a trial presented at ESMO 2019 may be a breakthrough when it comes to molecularly targeted treatment for prostate cancer.

Mushrooms reportedly have anticancer and antitumor properties, so researchers in Japan investigated to see if there was a link between mushroom intake and prostate cancer.

STUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.

How much do you know about the incidence and screening of prostate cancer? Here's your chance to find out.

Prostate cancer is the most frequent cancer found in American men, and the second leading cause of cancer death in this population. Currently, scores of reputable clinical trials are underway and recruiting patients.

A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.

Researchers looked at data from the Surveillance, Epidemiology, and End Results database to see if there has been any increase in the use of active surveillance or watchful waiting when it comes to low-risk prostate cancer.

The study compared PET/CT tracers over 18F-fluciclovine when it comes to the localization of biochemical recurrence of prostate cancer following radical prostatectomy.

Test your knowledge of metastatic prostate cancer with this month's quiz.

Researchers conducted gene expression analyses on prostate cancer tumor samples from World Trade Center first responders and general population patients to see if there were any differences between the two.